PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Describe the prevalence of ID in patients with HF and its impact on patient outcomes and quality of life, Interpret laboratory results for diagnosing and monitoring iron status in patients with HF, Apply current clinical guidelines and clinical trial results for iron therapies to improve outcomes in patients with ID and HF.

Go online to PeerView.com/PFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, cardiologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with or at risk for NVAF. Upon completion of this activity, participants should be better able to: Employ various evidence-based screening methods to identify patients with undiagnosed NVAF, Engage in shared decision-making with patients with NVAF about the benefits and limitations of anticoagulant therapies to reduce the risk of stroke in the context of anticoagulation stewardship.

Go online to PeerView.com/NXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances—in understanding of disease pathogenesis, emerging therapies, and new imaging approaches—have the potential to significantly improve care of individuals with multiple sclerosis (MS). The recognition of a central role for B lymphocytes in MS pathogenesis and development of two classes of therapeutic agents that target B cells—anti-CD20 antibodies and Bruton tyrosine kinase (BTK) inhibitors—facilitates the use of more novel disease-modifying therapies (DMTs). In addition, advances in imaging approaches can enhance diagnosis, disease monitoring, and treatment guidance. In this activity, based on a recent live webcast, our expert faculty will offer insight into the pathogenesis of MS, targeting B cells for the treatment of MS, and novel imaging approaches for monitoring disease status and treatment in relapsing MS. Upon completion of this activity, participants should be better able to: Summarize current perspectives on the roles of diverse cell types (eg, B and T lymphocytes, microglia, astrocytes) in the pathogenesis of relapsing MS, Apply individualized treatment regimens for relapsing MS by incorporating recent information on new and emerging therapies that target B lymphocytes, Compare available and novel imaging approaches for monitoring disease status and facilitating treatment decisions in relapsing MS.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/DKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder that can be fatal if left untreated. EGPA is characterized by moderate-to-severe asthma, peripheral blood eosinophilia, mononeuropathy or polyneuropathy, pulmonary infiltrates, paranasal sinus abnormalities, and extravascular eosinophils or eosinophilic vasculitis. Optimal treatment involves accurate diagnosis of the condition, keeping abreast of novel and emerging therapies, and a multidisciplinary approach. This web broadcast features two experts in EGPA as they aim to give a greater understanding into the recognition, diagnosis, and individualized management of EGPA. The event concludes with a practicum discussion to connect the data with real-life application. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of eosinophilic granulomatosis with polyangiitis (EGPA) and its relationship to novel therapeutic targets, Recognize the importance of a multidisciplinary approach in diagnosing and managing patients with EGPA, Apply evidence-based approaches to diagnose and differentiate EGPA from other eosinophilic disorders, Develop individualized treatment plans for patients with EGPA based on the latest clinical data.

Go online to PeerView.com/QQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potential of PARP inhibitors in cancer care include application of recommended testing strategies to guide patient selection, individualized treatment planning, and management of treatment-related toxicities. In this web broadcast, oncology and pharmacy experts review the latest evidence on the use of PARP inhibitors in the treatment of different tumors, including breast, ovarian, pancreatic, and prostate cancers, as well as oncology value assessment frameworks and strategies for assessing the benefits, risks, and costs to guide decisions regarding the use of this class of agents. Additionally, practical guidance is provided for optimizing outcomes for cancer patients who may benefit from PARP inhibitor therapy in managed care settings. Upon completion of this activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including ovarian, breast, pancreatic, prostate, and other malignancies, Assess the PARP inhibitors in terms of their mechanisms of action, efficacy and safety profiles, requirements for predictive testing to guide patient selection, nuances of administration and use, and other factors relevant to their value assessment in managed care settings, Implement appropriate decisions regarding the integration and use of PARP inhibitors in cancer care in managed care settings based on balanced assessments of all the evidence and unique characteristics of this class of agents.

Go online to PeerView.com/YAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert nephrologist discusses hyperkalemia in patients with hemodialysis-dependent chronic kidney disease (CKD) and explores the role of potassium binders in the treatment of hyperkalemia. Upon completion of this activity, participants will be able to: Differentiate currently available agents for the management of hyperkalemia according to their mechanisms of action, Apply current guidelines and best-available evidence to the management of hyperkalemia in patients with hemodialysis-dependent CKD.

Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance is shared to help match targeted therapies to each patient’s genomic alteration for improved outcomes. Experts discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice are also shared, along with recommendations and resources for patient education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance, Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others), Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection, Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care, Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors.